
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región.

Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región.
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile....
Fecha de publicación: 28 de agosto de 2022 Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies Ver más
Regulatory Pathway for Licensing Biotherapeutics in Mexico. VER MÁS
Determination of Peptide Profile Consistency and Safety of Collagen Hydrolysates as Quality Attributes. VER MÁS
Validation of a cell-based colorimetric reporter gene assay for the evaluation of Type I Interferons. VER MÁS
Taking advantage of a high-throughput flow cytometer for the implementation of an ADCC assay for regulatory compliance. VER MÁS
The yin/yang of inflammatory status: Blood-brain barrier regulation during sleep. VER MÁS
SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library VER MÁS

+52 (55) 5729 6000 Ext. 62543
Escuela Nacional de Ciencias Biológicas. Prolongación de Carpio y Plan de Ayala S/N, Del. Miguel Hidalgo, CDMX, C.P. 11340.
©2026 UDIBI